© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
August 2nd 2021, 8:00pm
Patient-reported outcome measures may have a small impact on predicting which patients with cirrhosis will be readmitted to the hospital.
July 31st 2021, 12:50pm
One diagnosis challenge is that there is no specific biomarker, either for autoimmune hepatitis (AIH) or metabolic-associated fatty liver disease (MAFLD), either alone or if they exist concurrently.
July 29th 2021, 8:30pm
A new report is issuing a call to action to develop a global strategy to address the growing issue of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
July 23rd 2021, 11:15am
The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.
July 21st 2021, 12:11pm
The current available studies on nutritional supplementation in nonalcoholic fatty liver disease (NALFD) highlight the need for more high-quality randomized controlled trials.
July 16th 2021, 2:00pm
A survey of global physicians found a gap in knowledge of non-alcoholic fatty liver disease (NAFLD) despite the growing burden of the disease worldwide.
July 13th 2021, 3:00pm
The problem of alcoholic liver disease is growing in the United States, and obtaining treatment is difficult.
July 10th 2021, 9:30pm
Coffee contains hundreds of chemical compounds and comes in several forms, and according to a recent study, has a protective effect on the liver, no matter what the type.
July 8th 2021, 8:30pm
A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.
July 1st 2021, 7:06pm
Manipulating the expression of MAGEA3 can help block the growth of hepatocellular carcinoma.